Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient
|
|
- Leonard Douglas
- 5 years ago
- Views:
Transcription
1 Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No L01-P Monday, October 17 1:30 p.m. 3:30 p.m. Convention Center: Rooms 319 & 320 Moderators: Heather A. Nyman, Pharm.D., BCPS Clinical Pharmacist, Dialysis, University of Utah Dialysis Program, Salt Lake City, Utah and Angela Q. Maldonado, Pharm.D., BCPS Clinical Assistant Professor of Pharmacotherapy, Washington State University; Kidney Transplant Pharmacist, Providence Hospital, Spokane, Washington Agenda 1:30 p.m. Introduction and Welcome 1:40 p.m. Mineral and Bone Disorder in Chronic Kidney Disease and Kidney Transplantation Timothy M. Clifford, Pharm.D., BCPS Clinical Pharmacist Specialist Transplant/Critical Care; Assistant Adjunct Professor, Pharmacy and Surgery, University of Kentucky, Lexington, Kentucky 2:15 p.m. Anemia Pre- and Post-renal Transplant Shouldn t the Allograft Be the Cure? Joanna Q. Hudson, Pharm.D., FASN, BCPS Associate Professor, The University of Tennessee, Departments of Clinical Pharmacy & Medicine (Nephrology), Memphis, Tennessee 2:50 p.m. The Pharmacokinetics and Pharmacodynamics of Drug Dosing in the Renal Allograft Recipient Ali Olyaei, Pharm.D. Professor of Medicine, Director of Clinical Research, Division of Nephrology and Hypertension, Oregon State University/Oregon Health & Sciences University, Portland, Oregon 3:25 p.m. Closing Remarks Faculty Conflict of Interest Disclosures Timothy M. Clifford: no conflicts to disclose. Joanna Q. Hudson: speaker s bureau for Amgen. Ali Olyaei: no conflicts to disclose. Annual Meeting Long-term Management of the Renal Transplant Recipient 1
2 Learning Objectives 1. Discuss the pathophysiology of mineral and bone disorder (MBD)in the CKD patient. 2. Discuss the prevalence of MBD in the kidney transplant recipient. 3. Describe the methods of diagnosing MBD, goals of management and monitoring parameters. 4. Recommend non-pharmacological and pharmacological treatment of MBD. 5. Discuss the pathophysiology of anemia both pre- and post-renal transplant. 6. Describe the goals of therapy and pharmacological management of anemia. 7. Describe the conflicting data on target hemoglobin with the use of erythropoiesis stimulating agents. 8. Describe the various methods of estimating GFR in the renal allograft recipient. 9. Discuss the use of potentially nephrotoxic medications in the renal allograft recipient and how to minimize nephrotoxicity. 10. Discuss how the varying degree of renal insufficiency affects the pharmacokinetics and pharmacodynamics of the immunosuppressants. Self-Assessment Questions Self-assessment questions are available online at Annual Meeting Long-term Management of the Renal Transplant Recipient 2
3 Anemia Pre- and dpost-renal tr Transplant Shouldn t the Allograft Be the Cure? Joanna Hudson, Pharm.D., BCPS, FASN Associate Professor Departments of Clinical Pharmacy & Medicine (Nephrology) The University of Tennessee Memphis, TN
4 Objectives Discuss the pathophysiology of anemia both pre- and post-renal transplant Describe the goals of therapy and pharmacological management of anemia Describe the conflicting data on target hemoglobin with the use of erythropoiesis stimulating agents
5 Erythropoiesis in CKD Bone Marrow Circulation Erythropoietin Iron Stem Cell BFU-E CFU-E Proerythroblast Reticulocyte RBCs Time to Mature Cell Development (days) JH Brook et al. Iron Metabolism in Health and Disease. 1 st edition. London, England: W.B. Saunders; 1994.
6 Response to RBC Mass Plasm ma Erythr ropoietin (U/liter) Normal Kidney Function Patients with Anemia and Normal Blood Donors 10 5 Normal Blood Donors Patients with Anemia (U/liter) Plasm ma Erythr ropoietin Kidney Disease Patients on Dialysis 10 5 Patients with Kidneys Patients without Kidneys Hematocrit Hematocrit Erslev AJ. N Engl J Med. 1991;324:
7 Contributing Factors of Anemia Associated With CKD Erythropoietin deficiency & resistance Chronic blood loss Shortened RBC lifespan from 120 to ~60 days Iron losses (iron deficiency) GI bleeding Reduced intake & absorption Malnutrition Inflammatory conditions Hemodilution Secondary Hyperparathyroidism Other disease states (e.g. cancer, HIV)
8 Body Iron Distribution and Pathways: Hemodialysis i Patient t Reticuloendothelial th li l stores (low) ferritin 50 to 800 Gut Tissue Transferrin Absorption 0.5 mg/day 32 mg/day 200 mg 1.5 mg = 50 µg/% (20% sat) Erythroid marrow 36 mg/day Red blood cells 1500 mg (Hct 30) Adapted from Bothwell et al. Iron Metabolism in Man. 2nd ed Loss: 1 mg/day Loss: 4 mg/day Net loss: 4.5 mg/day
9 Clinical and Economic Impact of Anemia Increased Mortality, Increased LVH 1-3 Decreased Quality of Life 4 Increased Hospitalization and Length of Stay 5 1. Harnett et al. Am J Kidney Dis. 1995;25(4 suppl 1):S3-S7. 2. Ma et al. J Am Soc Nephrol. 1999;10: Levin et al. Am J Kidney Dis. 1996;27: Strippoli et al. J Am Soc Nephrol. 2004;15: Jones et al. Kidney Int. 2004;65:
10 Lower HCT Associated With Increased Mortality in ESRD Patients t k All-cause death Cardiac-related related death *Re elative Ris < 27% 27% to < 30% 30% to < 33% 33% to < 36% *After adjustment for medical diseases. Ma et al. J Am Soc Nephrol ;10: Hct N = 75,283
11 Anemia Post Transplant At time of kidney transplantation almost all patients have anemia of CKD Post-transplantation anemia (PTA) is estimated to occur in 30-40% of patients Anemia usually resolves by 3-6 months, but some patients have late PTA defined as anemia 6 to 12 months after transplant Use of ESAs in kidney transplant recipients is y p p relatively low
12 Mechanisms of PTA Decreased RBC Production Drug induced d (immunosuppressants, ACEIs/ARBs, antimicrobial agents) Allograft dysfunction and rejection Erythropoietin resistance (iron deficiency, infections, aplastic anemia) Loss of RBCs Surgical blood loss GI blood loss Frequent phlebotomy
13 Mechanisms of PTA Increased RBC destruction Immune-mediated d hemolysis (immunosuppression, i PTLD) Microangiopathic hemolytic anemia (tacrolimus, cyclosporine, sirolimus) Nonimmune hemolysis (G6PD deficiency dapsone, ti trim/sufla, hemoglobinopathies) Other factors Donor and recipient factors Limitations of iron indices in transplant population Elevated hepcidin levels
14 Immunosuppressive Medications and Anemia Antimetabolite medications (azathioprine, MMF, mycophenolic acid) bone marrow suppression mtor inhibitors (sirolimus, everolimus) myelosuppression ess o and other mechanisms s Hemolytic anemia with sirolimus and the Hemolytic anemia with sirolimus and the calcineurin inhibitors tacrolimus and cyclosporine
15 Role of Hepcidin in Iron Metabolism Hormone produced primarily in the liver Principal regulator or iron absorption and distribution into tissues hepcidin blocks iron absorption hepcidin increases iron absorption Iron deficiency, Increased erythropoiesis Inflammation, Increased iron stores Hepcidin Hepcidin
16 Prevalence of PTA Male Mild: Hb > g/dl Moderate: Hb > g/dl Severe: Hb 11 g/dl Female Hb > g/dl Hb > g/dl Hb 10 g/dl Vanrenterghem et al. Am J Transplant 2003;3:835.
17 Prevalence of PTA ESA therapy was used in 5.2% of patients overall and in 18% of patients with severe anemia. Vanrenterghem et al. Am J Transplant 2003;3:835.
18 Prevalence of PTA Mix et al. Am J Transplant 2003;3:1426. Among pts with Hct < 30% 36% had iron studies 46% received iron 40% ESA
19 Association with GFR Mix et al. Am J Transplant 2003;3:1426.
20 Consequences in Transplant? Anemia significantly associated with mortality (hazard ratio 1.69; 95% CI ) 1 graft failure (hazard ratio 2.47; 95% CI ) 1 Left ventricular growth 2 Anemia not related to all-cause mortality but associated with 25% risk of allograft loss (hazard ratio 1.25; 95% CI ) 3 1 Molnar et al. Am J Transplant 2007;7: Rigatto et al. J Am Soc Nephrol 2003;14: Winkelmayer et al. Nephrol Dial Transplant 2006;21:3559.
21 Consequences in Transplant? Not a clear consensus than anemia is associated with increased mortality and adverse CV events in transplant population Anemia may not directly cause adverse outcomes in transplant population, but may be a marker for an underlying pathologic process
22 Goals in Transplant Patient QUALITY OF LIFE TRANSFUSIONS RISK OF ALLOGRAFT LOSS Balance goals while minimizing the risks of treatment.
23 Approach to Prevention and Treatment Perioperatively: Consider iron for patients with transferrin saturation < 20% and serum ferritin < 200 ng/ml Consider ESA therapy when benefit Consider ESA therapy when benefit outweighs risk
24 K/DOQI Guidelines for Anemia Management in the Transplant Population Recommend that treatment guidelines for anemia in the general CKD population be followed in the transplant population ESAs Early Post-transplantation Studies support that ESAs are effective in correcting anemia, although higher doses may be required compared to doses pre-transplant ESAs Late Post-transplantation spa a o ESAs are effective and do not likely accelerate a decline in renal function May contribute to hypertension Am J Kidney Dis. 2006;47(suppl 3):S1-S146.
25 Guidelines for Anemia of CKD CKD diagnosis Hb <12 g/dl (females) Hb <13.5 g/dl (males) Evaluate RBC, reticulocytes, iron parameters Iron deficient Correct iron deficiency (oral, parenteral) Normal Erythropoietic Stimulating Agent (ESA) No Anemia corrected Hb < 1 g/dl 4 weeks after dose change Increase doses by 25% Measure Hb every week until stable, then every 4 weeks Hb > 1 g/dl in 2 wk period Decrease doses dose by 25% Adapted from: National Kidney Foundation. Am J Kidney Dis. 2001;37(suppl 1):S182-S237, Am J Kidney Dis. 2006;47(suppl 3):S1-S146 and Epoetin PI June 2011.
26 What is known about ESAs in the transplant t population? ESA therapy post-transplanttransplant shortens time to achieve higher hematocrit and improves QOL 1,2 Observational studies in kidney transplant show evidence of increase mortality with Hb levels above 12.5 g/dl 3 Medicare e reimbursement e polices affect therapy 1 Van Loo et al. Nephrol Dial Transplant 1996;11: McDevitt et al. Am J Transplant 2005;5: Heinze et al. BMJ 2009;339:b4018.
27 Questions about ESAs in the transplant population? Can we apply data from ESA studies in CKD population? When do we start treatment and how aggressive should we be? What is the target Hb?
28 Concerns with ESAs and Target Hb in CKD
29 Mean monthly hemoglobin & mean EPO dose per week United States Renal Data System (USRDS) 2006 Annual Data Report
30 Safety Information on ESAs: Supporting Studies WARNINGS: Increased Mortality and Serious Cardiovascular Events Study Patients Sponsor Published Target Hb (g/dl) Besarab et al 1 Epoetin alfa Cardiac disease on hemodialysis Amgen ± 1 * vs 10 ± 1 CHOIR 2 Epoetin alfa Anemia associated with CKD not on dialysis Ortho Biotech/ J & J * vs 11.3 F. CREATE 3 Anemia associated with CKD not on Hoffmann Epoetin beta dialysis La Roche g/dl vs g/dl 1. Besarab A, et al. NE Engl ljm Med. 1998;339: CHOIR = Correction of Hemoglobin and Outcomes in Renal Insufficiency i 2. Singh AK, et al. N Engl J Med. 2006;355: CREATE = Cardiovascular Risk Reduction by Early Anemia Treatment 3. Drüke, et al. N Eng J Med 2006:355: with Epoetin Beta
31 CHOIR Trial Primary endpoints: time to composite death, MI, stroke, death, CHF hospitalization 1432 patients enrolled 715 assigned to high-hb group (13.5 g/dl) 717 assigned to low-hb group (11.3 g/dl) 312 completed 36 months or withdrew at study termination without having primary event 125 had a primary event 278 withdrew before early termination of study 131 required renal replacement therapy (RRT) 147 withdrew for other reasons 349 completed 36 months or withdrew at study termination without having primary event 97 had a primary event 271 withdrew before early termination of study 111 required RRT 160 withdrew for other reasons Singh AK, et al. N Engl J Med. 2006;355:
32 CHOIR Study Singh AK, et al N Engl J Med. 2006;355(20): Primary Composite End Point N = High-hemoglobin hemoglobin group y of Event robability mposite E Pr Com Low-hemoglobin group Month 222 composite events (death, MI, hospitalization for CHF, stroke) High-Hb (13.5 g/dl): 125 events (18%) Low-Hb (11.3 g/dl): 97 events (14%) Hazard ratio (HR) = 1.34; 95% Confidence Interval (CI), 1.03 to 1.74 (P = 0.03)
33 CREATE Study 603 patients with CKD stage 3 or 4 randomly assigned to 1 of 2 groups: Epoetin beta therapy targeted to Hb g/dl Epoetin beta therapy targeted to Hb g/dl Primary endpoint was time to first cardiovascular event Secondary endpoints were LVMI, QOL, and progression of CKD Drüeke TB, et al, for the CREATE Investigators. N Engl J Med. 2006;355(20):
34 Median Hemoglobin Levels in the Intention-to-Treat Population During the Study (g/dl) oglobin Hem Group 1 (n=301) Group 2 (n=302) Months Drüeke, T. et al., N Engl J Med 2006;355:
35 ee Survi val (%) Event-Fr Time to Primary End Point of First Cardiovascular Event Group 2 Lower Hb Group 1 Higher Hb 58 events in group 1 vs. 47 events in group 2 Hazard ratio 0.78; 95% CI 0.53 to 1.14; 14; P = Month Drüeke, T. et al., N Engl J Med 2006;355:
36 CREATE Study There was no difference between the groups in the primary endpoint, LVMI, or progression of CKD QOL increased significantly in both groups, but was significantly better in the higher Hb group compared with the lower Hb group at yr 1 Drüeke TB, et al, for the CREATE Investigators. N Engl J Med. 2006;355(20):
37 Meta-Analysis of CKD Trials p= Phrommintiku, Haas, Elsik, Krum. Lancet 2007; 369:
38 FDA Reaction to Safety Information on ESAs FDA issued warning in late 2006 regarding g new risks associated with use of ESAs FDA changed labeling for ESA on March 9, 2007 The use of ESAs may increase the risk for death and for serious cardiovascular events when dosed to achieve a target hemoglobin of >12 g/dl FDA recommends using the lowest dose of ESAs that will gradually raise the hemoglobin concentration to the lowest level sufficient to avoid the need for blood transfusion FDA Web page. Information for healthcare professionals: erythropoiesis stimulating agents (ESA). Available at: Accessed April 5, 2007.
39 Black Box Warning for ESAs in CKD Renal failure: Patients experienced greater risks for death and serious cardiovascular events when administered erythropoiesisstimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs g/dl; 14 vs. 10 g/dl) in two clinical studies. Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dl. Epogen PI, Amgen Inc. - August 2008
40 K/DOQI Update of Hb Target Adequate Hb Lower limit of Hb (Recommendation) In dialysis and nondialysis CKD patients receiving i ESA therapy, the selected Hb target should generally be in the range of g/dl Upper limit of Hb (Guideline) In dialysis and nondialysis CKD patients receiving ESA therapy, the Hb target should not be above 13 g/dl Strength of evidence = moderate KDOQI. Am J Kidney Dis. 2007;50:
41 TREAT: Trial to Reduce Cardiovascular Events with Aranesp (Darbepoetin alfa) Therapy Hypothesis: Treatment of anemia with darbepoetin reduces the risk of mortality and cardiovascular events and ESRD in patients with CKD and type 2 diabetes N = 2012 Darbepoetin Group (Target Hb 13 g/dl) Study Population Hb 11 g/dl GFR ml/min Type 2 DM TSat 15% N = 4038 Design randomized (1:1), double blind, controlled N = 2026 Control Group Placebo group subjects could receive darbepoetin when Hb < 9 g/dl Pfeffer et al. N Eng J Med 2009;361:
42 Primary Endpoints Time to: TREAT Endpoints Composite outcome of death from any cause or a CV event defined as: Nonfatal myocardial infarction Congestive heart failure Stroke Hospitalization for myocardial ischemia Composite of death or ESRD Secondary Endpoints Time to: Death Death from CV causes Rate of decline in egfr Change in patient reported fatigue (FACT-fatigue) Pfeffer et al. N Eng J Med 2009;361:
43 TREAT End Points Pfeffer et al. N Eng J Med 2009;361: Median Hb 12.5 ( ) 12.8) in darbepoetin group; 10.6 ( ) in placebo group (p<0.0001).
44 TREAT TREAT failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, CV morbidity, or ESRD and in time to all-cause mortality or ESRD. There was an almost two-fold increase in risk of stroke (5% in treatment arm vs. 2.6% in placebo arm) Among darbepoetin treated subjects with a past history g p j p y of cancer, there were more deaths due to all causes and due to cancer compared with the control group
45 FDA Urges Lower Doses of Anemia Drugs Reported that the FDA "said that three drugs that had been widely used to treat anemia in both kidney and cancer patients were so dangerous to the heart that doctors should consider avoiding the medicines altogether in some patients and using less of them in others." The FDA "concluded that there were no risk-free doses of Epogen (epoetin alfa), Aranesp (darbepoetin alfa) and Procrit (epoetin alfa), and that doctors should use the medicines only in patients suffering from severe anemia. New York Times (6/24/2011)
46 Most Recent Black Box Warning for ESAs in CKD Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesisstimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dl. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions. Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse events. Epogen PI, Amgen Inc. June 2011
47 Labeling of ESAs For patients with CKD on dialysis: Initiate Epogen treatment when the hemoglobin level is less than 10 g/dl. If the hemoglobin level approaches or exceeds 11 g/dl, reduce or interrupt the dose For patients with CKD not on dialysis: Consider initiating Epogen treatment only when the hemoglobin level is less than 10 g/dl and the following considerations apply: The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion and, Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal If the hemoglobin level exceeds 10 g/dl, reduce or interrupt the dose of Epogen, and use the lowest dose of Epogen sufficient to reduce the need for RBC transfusions. Epogen PI, Amgen Inc. June 2011
48 Questions Are negative outcomes associated with ESAs specifically or Hb level l or both? What is the Hb level at which QOL is maximixed, yet risk is minimized? Is iron a contributing factor or would increased use be supported to achieve target Hb without increased use of ESAs? What to do with conflicting FDA warnings and K/DOQI anemia guidelines?
49 Considerations in the Transplant Population Consider the risk of CV events and stroke in transplant recipients before initiating an ESA If blood transfusions are likely to be needed given the decline in Hb consider potential benefit of ESAs at low Hb (< 10 g/dl?) Until further guidance is available in the transplant population consider recommendations for ESA use in CKD patients not on dialysis
50 Summary Anemia of CKD is prevalent in patients post-kidney transplant and a problem many practitioners will be faced with given the increase in the population with ESRD. Iron supplementation and ESAs are essential for treatment of anemia of CKD; however, practitioners need to be cognizant of the limitations in using these agents. Recent evidence of mortality risk associated with higher Hb in select populations has raised many questions about the current strategies for anemia management. Whether the same risks of ESA use observed in the CKD population apply to kidney transplant patients has not been determined; however, there is enough information on ESAs to justify caution when making treatment t t decisions i for individuals with anemia post transplant.
Moderators: Heather A. Nyman, Pharm.D., BCPS Clinical Pharmacist, Dialysis, University of Utah Dialysis Program, Salt Lake City, Utah
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P (Knowledge-Based Activity) Monday, October 17 1:30
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationAnemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins
Anemia Update Peter Bárány Department of Renal Medicine/ Karolinska University Hospital and Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska Institutet,
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationCurrent Controversies in Anemia: Target Hemoglobin levels and Outcomes Robert Toto, MD
Current Controversies in Anemia: Target Hemoglobin levels and Outcomes Robert Toto, MD Director of Patient-Oriented Research in Nephrology Mary M Conroy Professor of Kidney Diseases Department of Medicine
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationFuture Direction of Anemia Management in ESRD. Jay B. Wish, MD 2008 Nephrology Update March 20, 2008
Future Direction of Anemia Management in ESRD Jay B. Wish, MD 2008 Nephrology Update March 20, 2008 The Evidence Normal Hct Study and CHOIR demonstrate adverse outcomes in ESA patients with target Hgb
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationARANESP (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationErythropoiesis-Stimulating Agents
Erythropoiesis-Stimulating Agents Policy Number: 5.01.04 Last Review: 8/2017 Origination: 8/2015 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationMedical Policy. MP Erythropoiesis-Stimulating Agents
Medical Policy BCBSA Ref. Policy: 5.01.04 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Prescription Drug Related Policies 1.01.24 Interferential Current Stimulation 2.01.21 Temporomandibular
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc., a Pfizer company, at , or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT (epoetin
More informationFDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ES...
Page 1 of 5 Home> Drugs> Drug Safety and Availability> Postmarket Drug Safety Information for Patients and Providers Drugs FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit,
More informationPROCRIT (epoetin alfa) for Injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. PROCRIT (epoetin alfa)
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationErythropoiesis Stimulation and Heart Failure: Current Status
Erythropoiesis Stimulation and Heart Failure: Current Status Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationPeer Review Report. [erythropoietin-stimulating agents]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [erythropoietin-stimulating agents] (1) Does the application adequately address the issue of the public health need
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005
Generic Brand HICL GCN Exception/Other DARBEPOETIN ALFA IN ARANESP 22890 POLYSORBATE EPOETIN ALFA EPOGEN, 04553 PROCRIT METHOXY PEG-EPOETIN BETA MIRCERA 35005 GUIDELINES FOR USE NOTE: Requirements regarding
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationChapter 3: Use of ESAs and other agents* to treat anemia in CKD Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 3 & 2012 DIGO Chapter 3: Use of ESAs and other agents* to treat anemia in CD idney International Supplements (2012) 2, 299 310; doi:10.1038/kisup.2012.35 ESA
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationManagement of anemia in CKD. Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan
Management of anemia in CKD Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan Shiga toxin Kiyoshi Shiga 1871-1957 Shiga toxin binds to
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationCorporate Medical Policy Erythropoiesis-Stimulating Agents (ESAs)
Corporate Medical Policy Erythropoiesis-Stimulating Agents (ESAs) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: erythropoiesis_stimulating_agents_(esas) 8/2011 3/2018 3/2019 6/2018
More informationPROCRIT DOSAGE AND ADMINISTRATION PROCRIT
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. injection, for intravenous
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationThe use of surrogates as key performance indicators
REPLY The use of surrogates as key performance indicators Dr José Vinhas Department of Nephrology, Centro Hospitalar de Setúbal. Setúbal, Portugal Received for publication: 24/08/2012 Accepted: 31/08/2012
More informationErythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera )
Erythropoiesis-Stimulating Agents (ESA s): epoetin alfa (Epogen and Procrit ), darbepoetin alfa (Aranesp ), and pegylated epoetin beta (Mircera ) Applies to all products administered or underwritten by
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationCOMPARISON OF EXISTING ANEMIA GUIDELINES WORLDWIDE. R Vanholder, University Hospital, Gent, Belgium
COMPARISON OF EXISTING ANEMIA GUIDELINES WORLDWIDE R Vanholder, University Hospital, Gent, Belgium Comparative data regarding target Hgb levels Origin Year Target Comments Evidence CARI 2005 11 g/dl
More informationStudy of Management of anemia in Chronic Kidney Disease Patients
Review Article Study of Management of anemia in Chronic Kidney Disease Patients Meby Susan Mathew, Nama Ravi Sneha Keerthi, Neelathahalli Kasturirangan Meera* Meera N.K, Visveswarapura Institute of Pharmaceutical
More informationPROs for Drug Development. Melanie Blank, MD
PROs for Drug Development in Chronic Kidney Disease Melanie Blank, MD Disclaimer The views expressed here represent my opinions and do not necessarily represent the views of the FDA. Overview Stagnation
More informationHemodialysis patients with endstage
Insights into Achieving Target Hemoglobin Levels: Increasing the Serum Ferritin Parameter Scott Bralow, DO Dr. Scott Bralow is the Medical Director of the Renal Center of Philadelphia. Evidence suggests
More informationGuideline Summary NGC-6019
NGC banner Guideline Summary NGC-6019 Guideline Title (1) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. (2) 2007 update of hemoglobin target.
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationAnemia Management: Using Epo and Iron
Anemia Management: Using Epo and Iron Ky Stoltzfus, MD University of Kansas Medical Center Assistant Professor Department of Internal Medicine January 23, 2013 Regulation of red cell production Treatment
More informationErythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses
BJMP 2009:2(3) 12-20 Review Article Erythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses analyses Amir Hayat
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationClinical Policy Title: Erythropoietin for end-stage renal disease
Clinical Policy Title: Erythropoietin for end-stage renal disease Clinical Policy Number: 00.02.07 Effective Date: June 1, 2015 Initial Review Date: February 19, 2014 Most Recent Review Date: January 18,
More informationEPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
PATIENT BLOOD MANAGEMENT DALLA TEORIA ALLA PRATICA 16 FEBBRAIO 2018 EPO e Ferro in Emodialisi: Il PBM al suo esordio Lucia Del Vecchio Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationDisclosures. Topics. Staging and GFR. K-DOQI Staging of Chronic Kidney Disease. Definition of Chronic Kidney Disease. Chronic Kidney Disease
Disclosures Chronic Kidney Disease Consultant: Baxter Healthcare J. Kevin Tucker, M.D. Brigham and Women s Hospital Massachusetts General Hospital Topics Staging of chronic kidney disease (CKD) How to
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationClinical UM Guideline
Subject: Guideline #: Current Effective Date: 12/28/2016 Status: Reviewed Last Review Date: 11/03/2016 Description This document addresses recombinant, or man-made, erythropoietin products: Aranesp (Darbepoetin
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationPost Transplant Anaemia
11 Post Transplant Anaemia Bhadran Bose and David Mudge Princess Alexandra Hospital, Brisbane Australia 1. Introduction Anaemia, as a complication of end stage kidney disease (ESKD), is well studied (Eschbach
More informationAnaemia in the ICU: Is there an alternative to using blood transfusion?
Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationPROCRIT (epoetin alfa)
PROCRIT (epoetin alfa) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT.
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationPreoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD
Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia is common, especially in patients undergoing nonemergent high-blood-loss surgical
More informationErythropoiesis-Stimulating Agents (ESA s): Epoetin (Epogen and Procrit ), and Darbepoetin (Aranesp )
Erythropoiesis-Stimulating Agents (ESA s): Epoetin (Epogen and Procrit ), and Darbepoetin (Aranesp ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationAnemia is very common among end-stage renal fail LATEST STRATEGY IN RENAL ANEMIA MANAGEMENT IN PERITONEAL DIALYSIS PATIENTS.
Proceedings of the 3rd Asian Chapter Meeting of the ISPD November 22 24, 2007, Hiroshima, Japan Peritoneal Dialysis International, Vol. 28 (2008), Supplement 3 0896-8608/08 $3.00 +.00 Copyright 2008 International
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationEfficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia
Research Article Efficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia Diana Laila Ramatillah* 1, Syed Azhar Syed Sulaiman 1, Amer Hayat Khan 1, Ong Loke Meng 2,
More informationPrevalence of Anemia among Iraqi Patients after Renal
Original Article Prevalence of Anemia among Iraqi Patients after Renal Transplantation * Qais H. Al-Tai ** Intisar Y. Al-Ani** BSc, MSc, PhD Sc MBChB, FICMS BSc, MSc Fac Med Baghdad 2011; Vol. 53, No.
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL TABLE OF CONTENTS: Hemoglobin Status Assessment ------------------------------------------- Page 1
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationErythropoietins Data Points #4
Trends in the utilization of erythropoiesis-stimulating agents among Medicare beneficiaries with kidney disease Erythropoietins Data Points #4 Chronic renal disease affects more than 26 million Americans
More informationThe Role of Erythropoiesis-Stimulating Agents in the Treatment of Anemia
n report n The Role of Erythropoiesis-Stimulating Agents in the Treatment of Anemia Steven Fishbane, MD Correction of Anemia and Impact on Quality of Life Proper treatment of anemia can improve a patient
More informationAnemia and Iron Deficiency: What Every Cardiologist Needs to Know
6th Saudi HF Group Symposium Riyadh - December 8-9, 2017 Anemia and Iron Deficiency: What Every Cardiologist Needs to Know Ammar Chaudhary MBChB, FRCPC Consultant Cardiologist Advanced Heart Failure Department
More informationErythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242
Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242 Last Review Date: 05/01/2018 Date of Origin: 10/17/2008 Dates Reviewed:
More informationDisease Pathogenesis and Research Progression of Renal Anemia
2018 3rd International Conference on Life Sciences, Medicine, and Health (ICLSMH 2018) Disease Pathogenesis and Research Progression of Renal Anemia Yingying Liu, Qi Jiang* Department of Nephrology, China-Japan
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study F. Dellanna, 1
More information